Kasper Lykke

The search for NKCC1-selective drugs for the treatment of epilepsy: Structure–function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A

Kasper Lykke, Kathrin Töllner, Peter W. Feit et al. · Epilepsy & Behavior · 2016 · 43 citations

Molecular Pharmacology, Nkcc1-selective Drugs, Various Bumetanide Derivatives +9

Expression of the human isoform of glutamate dehydrogenase, hGDH2, augments TCA cycle capacity and oxidative metabolism of glutamate during glucose deprivation in astrocytes

Jakob D. Nissen, Kasper Lykke, Malin H. Stridh et al. · Glia · 2016 · 42 citations

Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy

Claudia Brandt, Patricia Seja, Kathrin Töllner et al. · Neuropharmacology · 2018 · 42 citations · Full text

Medicine, Neurotransmitter, Neuropharmacology +8

Structure–activity relationships of bumetanide derivatives: correlation between diuretic activity in dogs and inhibition of the human<scp>NKCC</scp>2<scp>A</scp>transporter

Kasper Lykke, Kathrin Töllner, Kerstin Römermann et al. · British Journal of Pharmacology · 2015 · 21 citations · Full text

Cerebral influx of Na+ and Cl− as the osmotherapy-mediated rebound response in rats

Eva Kjer Oernbo, Kasper Lykke, Annette Buur Steffensen et al. · Fluids and Barriers of the CNS · 2018 · 19 citations · Full text